Assessment of Serum Urea, Creatinine and Uric Acid in Oral Cancer.
creatinine
metabolism
oral cancer
squamous cell carcinoma
urea
uric acid
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Jun 2022
16 Jun 2022
Historique:
received:
05
05
2022
revised:
12
06
2022
accepted:
14
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Oral squamous cell carcinoma (OSCC) is a common malignancy worldwide, leading to significant disease-associated social and financial burdens. The investigation of underlying mechanisms involved in carcinogenesis and tumor progression in OSCC might provide new therapeutic perspectives with an impact on disease control and patient survival. Our study aims to investigate the interrelation between metabolic processes, expressed through final catabolism products and clinicopathological characteristics in OSCC. This is a single cancer comparative retrospective study investigating metabolic byproducts, namely serum urea, creatinine and uric acid, detected at the moment of diagnosis in patients with OSCC, in comparison to healthy controls. Clinical and paraclinical data regarding exposure to risk factors, disease staging and pathological characteristics were collected for all patients. Subjects with co-existing systemic or metabolic diseases, or with a history of malignancy, were excluded from the study. Subsequently, the metabolic byproducts revealing significant changes in OSCC patients were considered for a correlation analysis with the disease clinico-pathological characteristics. Blood levels for urea, creatinine and uric acid were determined in a total of 225 subjects: 145 patients diagnosed with OSCC and 80 healthy control subjects admitted to our hospital between 2016 and 2021. The comparative analysis between groups revealed that the serum urea level was significantly lower in OSCC patients ( Decreased serum urea levels are detected in patients with advanced OSCC, in correlation with lymph node metastasis. The invasive features of tumor cells in OSCC might be promoted in association with dysregulation of protein catabolism processes, facilitating aggressive behavior in OSCC.
Sections du résumé
BACKGROUND
BACKGROUND
Oral squamous cell carcinoma (OSCC) is a common malignancy worldwide, leading to significant disease-associated social and financial burdens. The investigation of underlying mechanisms involved in carcinogenesis and tumor progression in OSCC might provide new therapeutic perspectives with an impact on disease control and patient survival. Our study aims to investigate the interrelation between metabolic processes, expressed through final catabolism products and clinicopathological characteristics in OSCC.
MATERIALS AND METHODS
METHODS
This is a single cancer comparative retrospective study investigating metabolic byproducts, namely serum urea, creatinine and uric acid, detected at the moment of diagnosis in patients with OSCC, in comparison to healthy controls. Clinical and paraclinical data regarding exposure to risk factors, disease staging and pathological characteristics were collected for all patients. Subjects with co-existing systemic or metabolic diseases, or with a history of malignancy, were excluded from the study. Subsequently, the metabolic byproducts revealing significant changes in OSCC patients were considered for a correlation analysis with the disease clinico-pathological characteristics.
RESULTS
RESULTS
Blood levels for urea, creatinine and uric acid were determined in a total of 225 subjects: 145 patients diagnosed with OSCC and 80 healthy control subjects admitted to our hospital between 2016 and 2021. The comparative analysis between groups revealed that the serum urea level was significantly lower in OSCC patients (
CONCLUSIONS
CONCLUSIONS
Decreased serum urea levels are detected in patients with advanced OSCC, in correlation with lymph node metastasis. The invasive features of tumor cells in OSCC might be promoted in association with dysregulation of protein catabolism processes, facilitating aggressive behavior in OSCC.
Identifiants
pubmed: 35743528
pii: jcm11123459
doi: 10.3390/jcm11123459
pmc: PMC9225481
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Med (Lausanne). 2021 Sep 28;8:745006
pubmed: 34651001
Healthcare (Basel). 2022 Feb 10;10(2):
pubmed: 35206956
Nature. 2017 Jun 1;546(7656):168-172
pubmed: 28538732
Cancer Manag Res. 2019 Feb 08;11:1321-1336
pubmed: 30799957
Front Oncol. 2021 Oct 07;11:710423
pubmed: 34692487
J Maxillofac Oral Surg. 2017 Jun;16(2):158-163
pubmed: 28439154
BMC Oral Health. 2019 Apr 27;19(1):62
pubmed: 31029131
Otolaryngol Head Neck Surg. 1983 Apr;91(2):119-25
pubmed: 6408567
J Am Coll Nutr. 1993 Feb;12(1):42-6
pubmed: 8440817
Metab Brain Dis. 2017 Apr;32(2):529-538
pubmed: 28012068
Oncoimmunology. 2020 Jun 1;9(1):1771142
pubmed: 32923127
Postgrad Med J. 1992 Mar;68(797):174-9
pubmed: 1589374
Nat Commun. 2019 Jul 5;10(1):3000
pubmed: 31278254
Cancers (Basel). 2021 Sep 05;13(17):
pubmed: 34503285
J Clin Med. 2019 Nov 07;8(11):
pubmed: 31703248
Cell. 2018 Sep 6;174(6):1559-1570.e22
pubmed: 30100185
PLoS One. 2010 Aug 11;5(8):e12107
pubmed: 20711410
J Cancer Res Clin Oncol. 2013 Jan;139(1):171-8
pubmed: 23007690
Clin Transl Med. 2012 Aug 15;1(1):16
pubmed: 23369448
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
Anal Cell Pathol (Amst). 2021 Oct 15;2021:2328218
pubmed: 34692375
Cancer. 2020 Mar 1;126(5):1090-1101
pubmed: 31722124
Sci Rep. 2020 May 12;10(1):7877
pubmed: 32398670
Cells. 2021 Apr 29;10(5):
pubmed: 33946927
Clin Chem. 2017 Jun;63(6):1151-1160
pubmed: 28428355
Exp Ther Med. 2022 May;23(5):364
pubmed: 35493435
Int J Cancer. 2013 Feb 1;132(3):E85-93
pubmed: 22815199
Clin J Am Soc Nephrol. 2006 Sep;1(5):909-14
pubmed: 17699306
BMC Med. 2013 Mar 04;11:60
pubmed: 23497222
Signal Transduct Target Ther. 2020 Mar 12;5(1):28
pubmed: 32296047
Oncol Rep. 2017 May;37(5):2727-2734
pubmed: 28393236
Genes (Basel). 2021 Mar 29;12(4):
pubmed: 33805346
Science. 2017 Nov 17;358(6365):941-946
pubmed: 29025995
Nat Rev Mol Cell Biol. 2000 Dec;1(3):225-8
pubmed: 11252898
Nat Rev Cancer. 2018 Oct;18(10):634-645
pubmed: 30194362
Cell Chem Biol. 2020 Mar 19;27(3):259-268.e5
pubmed: 32017919
Sci Rep. 2021 May 12;11(1):10058
pubmed: 33980952
Sci Rep. 2019 Jul 31;9(1):11129
pubmed: 31366905
J Clin Med. 2021 May 27;10(11):
pubmed: 34071843
Mol Cell. 2021 Sep 16;81(18):3749-3759
pubmed: 34469752
Int J Epidemiol. 2020 Oct 1;49(5):1517-1525
pubmed: 32984907
Front Cell Dev Biol. 2021 Apr 01;9:650748
pubmed: 33869206
J Pharm Bioallied Sci. 2019 May;11(Suppl 2):S107-S111
pubmed: 31198321
J Biol Chem. 2017 Dec 8;292(49):19952-19958
pubmed: 29084849
Front Immunol. 2018 Jul 30;9:1697
pubmed: 30105018
Cancer Treat Res Commun. 2020;25:100233
pubmed: 33161323
Anticancer Res. 2018 Sep;38(9):5127-5130
pubmed: 30194159
J Dent (Shiraz). 2013 Sep;14(3):146-50
pubmed: 24724136
Tumour Biol. 2014 Nov;35(11):11097-105
pubmed: 25099619
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
Cell Rep. 2021 May 11;35(6):109101
pubmed: 33979616
Annu Rev Nutr. 2002;22:87-105
pubmed: 12055339